In patients with resected stage II to IIIA non-small cell lung cancer (NSCLC) who received cisplatin-based chemotherapy, atezolizumab reduced the risk for disease recurrence or death compared with best supportive care (BSC), according to interim results from the phase 3 IMpower010 study.
Overall, patients treated with atezolizumab (Tecentriq, Genentech) had a 21% reduction in the risk for disease recurrence or death versus BSC (P=0.02), and those with levels of programmed death ligand-1